China National Medicines Corporation Ltd. provided earnings guidance for the first half of 2018. The company predicts that the net profit belonging to shareholders of the company in the 1st half of 2018 will increase by between RMB 55 million and RMB 110 million with an increase of between 10% and 20% compared with the same period of the year before. The net profit belonging to shareholders of the company after excluding extraordinary profit and loss will increase by between RMB 140 million and RMB 220 million with an increase of between 30% and 50% compared with the same period of the year before.